Management of Neuro-Behçet's Disease

Treatment Recommendations

• The European League Against Rheumatism recommends high-dose corticosteroids for acute attacks of parenchymal involvement, with a strength of evidence based on clinical guidelines 1
• The European League Against Rheumatism suggests immunosuppressive agents, including azathioprine, interferon-alpha, cyclophosphamide, methotrexate, and TNF-alpha antagonists, for parenchymal involvement, with a moderate level of evidence 1
• Cyclosporine A should be avoided in patients with central nervous system involvement due to potential neurotoxicity, as recommended by the European League Against Rheumatism, with a high level of evidence 1

Patient Risk Factors

• Young men with early disease onset have a higher risk of severe neurological involvement, according to clinical guidelines from the European League Against Rheumatism 2

Monitoring and Assessment

• Regular monitoring with clinical assessment and inflammatory markers is essential for patients with neuro-Behçet's disease, as suggested by clinical guidelines from the European League Against Rheumatism, with a moderate level of evidence 3